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Abstract
Background: Hyperuricemia is associated with obesity. The visceral adiposity and subcutaneous adiposity may be
associated with the differential metabolic risk, and the distribution of abdominal adipose tissue was significantly
altered in people with type 2 diabetes mellitus (DM) compared to healthy people. Our study was performed to
determine to the association between the regional abdominal adipose tissue distribution and serum uric acid
levels in people with type 2 DM.
Methods: A total of 699 people with type 2 DM and who had undergone abdominal computed tomography
assessment of the visceral fat area and subcutaneous fat area were included. The serum uric acid levels were
measured by the uricase method. Hyperuricemia was defined by cut-off value of > 7 mg/dl for men and > 6 mg/
dl for women.
Results: The visceral fat area was positively associated with the serum uric acid levels after adjustment for age, sex,
systolic blood pressure, diastolic blood pressure, serum creatinine, hemoglobin, serum albumin, serum high-density
lipoprotein, serum triglyceride and hemoglobin A1c (b-coefficient = 0.117, p < 0.001). The logistic regression
analysis showed that the visceral fat area was the significant independent predictor of hyperuricemia (OR 2.33, 95%
CI, 1.21-4.50, p = 0.012). But there was no significant association between the subcutaneous fat area and the serum
uric acid levels (b-coefficient = 0.061, p = 0.255).
Conclusions: our data shows that the visceral fat area was positively associated with the serum uric acid levels,
but the subcutaneous fat area was not in people with type 2 DM.
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Background
Hyperuricemia or elevated serum uric acid levels have
been considered not only an independent risk factor for
cardiovascular diseases but this also plays a role in the
development of metabolic diseases [1-4]. Previous stu-
dies reported that the serum uric acid level is associated
with the individual components of metabolic syndrome
such as obesity, dyslipidemia and hypertension [5,6]. As
for the association between the serum uric acid levels
and obesity, a number of epidemiological and clinical
studies have demonstrated a positive correlation
between the serum uric acid levels and obesity [5,7].
The visceral fat component and the subcutaneous fat
component may have differential metabolic risks [8].
The visceral fat component is metabolically active and it
regulates numerous adipocytokines and other vasoactive
substances, which may be associated with an increased
cardiometabolic risk [9-11]. As for the association
between the serum uric acid levels and the regional
abdominal adipose tissue distribution, previous studies
showed that the serum uric acid level was related with
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visceral fat accumulation as measured using computed
tomography (CT) or bioelectrical impedance analysis in
general populations [12-14].
Diabetes mellitus (DM) is associated with the cardio-
vascular complications of metabolic syndrome and obe-
sity is more prevalent in people with DM compared in
people without DM [15]. Furthermore, the distribution
of abdominal adipose tissue was significantly altered in
people with type 2 DM; the visceral fat component was
greater and the subcutaneous fat component was less in
the subjects with type 2 DM than that in the healthy
control subjects [16]. The association between the regio-
nal distribution of abdominal adipose tissue and the
serum uric acid levels in people with type 2 DM is not
well established. We hypothesized that the visceral fat
component would be more associated with the serum
uric acid levels, as compared to that of the subcutaneous
fat component, in people with type 2 DM. The aim of
our study is to determine the relationships between the
regional abdominal adipose tissue distribution and the
serum uric acid levels in people with type 2 diabetes
mellitus. Examining the influence of the regional
abdominal adipose tissue distribution on serum uric
acid levels may help to define it as a risk factor for the
cardiometabolic complications with type 2 DM.
Methods
Study Population
The present study included 699 subjects with type 2
DM and who had undergone abdominal CT for obesity
screening at the Bucheon Saint Mary’s Hospital between
July 2005 and December 2007. Type 2 DM was diag-
nosed if the patients with a fasting plasma glucose level
≥ 126 mg/dl or a 2-hr post-glucose level after a 75-g
oral glucose tolerance test ≥ 200 mg/dl. Patients who
were treated by diet alone or in combination with oral
hypoglycemic agents or they had fasting serum C-pep-
tide values greater than 1.0 ng/mL when administered
insulin were also categorized as type 2 DM. The exclu-
sion criteria were missing values for the body mass
index (BMI), the serum uric acid levels or the other
clinical variables. Among a total of 953 subjects with
type 2 DM and who had undergone abdominal CT for
obesity screening, 699 subjects were included in our
study. The study protocol was approved by the local
ethical committee, and this study was conducted accord-
ing to the principles of the Declaration of Helsinki.
Abdominal Adipose Tissue Measurements
Measurements of the cross-sectional abdominal visceral
and subcutaneous fat areas by CT (Somatom plus 4, Sie-
mens, Germany) were performed using an established
protocol [17]. The subjects were placed supine with
their feet first in the scanner and a cross-sectional scan
with a 10 mm slice thickness centered at the level of the
intervertebral space between the fourth and fifth lumbar
vertebrae was obtained with using a radiograph of the
skeleton as a reference to establish the position of the
scans to the nearest millimeter. The boundaries of the
subcutaneous and visceral fat areas were defined by tra-
cing their contours on the scans and the adipose tissue
areas were calculated by computing the fat area surfaces
with an attenuation range of -190 to -30 Hounsfield
units. The visceral fat area was measured within the
region by outlining the circumference of the muscle
wall surrounding the abdominal cavity. The total fat
area was measured in the region by outlining the cir-
cumference of the abdominal wall. The subcutaneous fat
area was calculated by subtracting the visceral fat area
from the total fat area. The measurements were done by
one radiologist who was blinded to the subjects’ clinical
and laboratory data. We tested the intra-observer repro-
ducibility. The visceral fat areas and subcutaneous fat
areas of the scans of a subset of 50 randomly selected
subjects were repeatedly measured by the radiologist.
The intraclass correlation coefficients for the visceral fat
areas and subcutaneous fat areas were 0.991 and 0.981,
respectively. For the inter-observer reproducibility, pre-
vious studies have reported that measurement of the
visceral fat areas and subcutaneous fat areas are repro-
ducible between observers [8,18].
Clinical Information and Laboratory Analysis
The clinical information was assessed from the written
and electronic medical records, and this information
included the medical history, the current medications
and the laboratory data. The collected data included
age, gender, the BMI, the systolic and diastolic blood
pressures, the duration of diabetes, the serum creatinine,
hemoglobin and albumin levels, the total cholesterol and
high-density lipoprotein (HDL) cholesterol levels, the
triglyceride and serum uric acid levels, the urinary albu-
min excretion rate, the homeostasis model for insulin
resistance (HOMA-IR) score, the lipoprotein (a) and
high-sensitivity C-reactive protein (hs-CRP) levels. Fast-
ing venous blood sample were taken for the determina-
tion of the serum level of total cholesterol, HDL
cholesterol and triglyceride and serum uric acid level
was measured on a standard autoanalyzer by the uri-
case-peroxidase method. Hyperuricemia was defined by
cut-off value of > 7 mg/dl for men and > 6 mg/dl for
women [19]. The urinary albumin excretion rate was
assessed via 24 hour urine collection. The BMI was cal-
culated as weight (kg)/height (m2). The blood pressure
was measured twice, 5 minutes apart, using a random
zero sphygmomanometer with the patient seated after
10 minutes of rest. The estimated GFR (eGFR) was cal-
culated using the Modification of Diet in Renal Disease
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four-variable equation at the time of CT scanning: eGFR
= 186 × serum creatinine-1.154 × age-0.203 × 1.212 (if
black) × 0.742 (if female). The HOMA-IR was calculated
with the following formula: [Fasting insulin (μIU/mL) ×
fasting plasma glucose (mmol/L)]/22.5 [20].
Statistics
The data for the continuous variables with a normal dis-
tribution is expressed as means ± SDs and the data for
the continuous variables without a normal distribution
is expressed as medians with interquartile ranges. The
Student’s t-test or Mann-Whitney test were used, as
appropriate, to determine differences in continuous vari-
ables. Categorical variables are presented as percentage.
The Pearson’s chi-square test was used to determine the
differences in categorical variables. Pearson correlation
coefficients were used to assess the simple correlation
between the regional abdominal adiposity measurements
such as the visceral fat area and subcutaneous fat areas
and the clinical parameters. Multivariate linear regres-
sion analysis was used to determine the association
between the abdominal adiposity measurements, includ-
ing the visceral fat area and the subcutaneous fat area
with the serum uric acid levels after adjustment for age,
sex, systolic blood pressure, diastolic blood pressure,
serum creatinine, hemoglobin, serum albumin, serum
HDL cholesterol, serum triglyceride and hemoglobin
A1c. Logistic regression analysis was used to estimate
odds ratios for hyperuricemia according to the cate-
gories of visceral fat areas. P values < 0.05 were consid-
ered statistically significant. The statistical analyses were
performed using SPSS 15.0 software (Chicago, IL, USA).
Results
Patients’ characteristics
Among a total of 699 subjects with type 2 DM, 389
(55.7%) were females and 310 (44.3%) were males. Table
1 shows the clinical characteristics of the study partici-
pants according to gender. The mean age was 55 ± 14
years old. The mean total fat area was 283 ± 125 Cm2.
The mean visceral fat area was 122 ± 61 Cm2 and the
mean subcutaneous fat area was 161 ± 83 Cm2. The
mean BMI was 25.2 ± 3.9 kg/m2. Female had significant
higher total fat area and subcutaneous fat area than
male (314 ± 121 Cm2 vs 245 ± 118 Cm2, p < 0.001 and
191 ± 82 Cm2 vs 122 ± 66 Cm2, p < 0.001, respectively).
Visceral fat area was not significantly different between
female and male (121 ± 58 Cm2 vs 125 ± 66 Cm2, p =
0.411). The mean level of serum uric acid was 4.6 ± 1.5
mg/dL. Female had significant lower uric acid levels
than male (4.2 ± 1.5 mg/dl vs 5.1 ± 1.5 mg/dl, p <
0.001). Hyperuricemia was note in 95 subjects thus giv-
ing an overall prevalence rate of 13.6%. The proportion
of hyperuricemia in male subject was higher than that
of hyperuricemia in female subject (25% vs 5%, p <
0.001).
Relationships between the serum uric acid levels and the
clinical parameters
We analyzed the relationships between the serum uric
acid levels and the clinical parameters (Table 2). The
serum uric acid levels were positively correlated with
the BMI, the visceral fat area, systolic blood pressure,
diastolic blood pressure, serum creatinine, hemoglobin,
serum albumin, serum triglyceride, urinary albumin
excretion, log HOMA-IR and log hs-CRP. The serum
uric acid levels were negatively correlated with eGFR,
serum HDL cholesterol and hemoglobin A1c. There was
no significant correlation between the serum uric acid
levels and the subcutaneous fat area. Figure 1 shows
Pearson’s correlation of the visceral fat area and the
subcutaneous fat area with the serum uric acid levels in
people with type 2 DM.
Association between the regional abdominal adipose
distribution and the serum uric acid levels
Table 3 shows the multivariate linear regression analysis
for the association of the regional abdominal adipose tis-
sue distribution with the serum uric acid levels. The
visceral fat area was positively associated with serum
uric acid levels after adjustment for age, gender, systolic
blood pressure, diastolic blood pressure, serum creati-
nine, hemoglobin, serum albumin, serum HDL choles-
terol, serum triglyceride and hemoglobin A1c (b-
coefficient = 0.117, p < 0.001). The BMI was also posi-
tively associated with the serum uric acid levels after
adjustment for the clinical parameters (b-coefficient =
0.184, p < 0.001). But there was no significant associa-
tion between the subcutaneous fat area and the serum
uric acid levels (b-coefficient = 0.061, p = 0.255). We
also analyzed the association of visceral fat area tertiles
for hyperuricemia in logistic regression model, which
included age, gender, systolic blood pressure, diastolic
blood pressure, eGFR and serum triglyceride as indepen-
dent variables (Table 4). The odds ratio (OR) of the
third tertile of visceral fat area was 2.33 (95% CI, 1.21-
4.50, p = 0.012), which was statistically significant
increases for the incidence of hyperuricemia in the
group with high visceral fat area.
Discussion
In the present study, we demonstrated that the visceral
fat area were positively associated with the serum uric
acid levels and predictive for the hyperuricemia in sub-
jects with type 2 DM, but the subcutaneous fat area was
not significantly associated with the serum uric acid
levels. In our knowledge, this is a first report for the
association between the regional abdominal adipose
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tissue distribution and the serum uric acid levels in sub-
jects with type 2 DM, in which the distribution of the
abdominal adipose tissue was significantly altered as
compared to that of the subjects with normal glucose
tolerance. The amount of visceral fat area was greater
and the amount of subcutaneous fat area was less in
people with type 2 DM than that in the people with
normal glucose tolerance [16].
Some previous studies that focused on general popula-
tions reported that the serum uric acid levels were posi-
tively correlated with both the visceral fat area and the
subcutaneous fat area; particularly, the serum uric acid
levels were more closely correlated with the visceral fat
[12-14]. Matsuura et al. reported that the serum uric
acid levels were higher in both the subcutaneous obesity
group and the visceral obesity group of male obese sub-
jects than that in the non-obese control group [12].
They also showed that urinary uric acid excretion was








Age, years 55 ± 14 51 ± 13 58 ± 14 < 0.001
BMI, kg/m2 25.2 ± 3.9 24.6 ± 3.5 25.5 ± 4.2 0.003
Total fat area, Cm2 283 ± 125 245 ± 118 314 ± 121 < 0.001
Visceral fat area, Cm2 122 ± 61 125 ± 66 121 ± 58 0.411
Subcutaneous fat area, Cm2 161 ± 83 122 ± 66 191 ± 82 < 0.001
Systolic blood pressure, mmHg 131 ± 17 132 ± 17 131 ± 16 0.719
Diastolic blood pressure, mmHg 79 ± 11 79 ± 12 79 ± 10 0.591
Duration of diabetes, months 69 ± 87 50 ± 73 84 ± 94 < 0.001
Serum uric acid, mg/dL 4.6 ± 1.5 5.1 ± 1.5 4.2 ± 1.5 < 0.001
Hyperuricemia, n (%) 95 (14) 77 (25) 18 (5) < 0.001
Serum creatinine, mg/dL 0.9 ± 0.5 1.0 ± 0.4 0.9 ± 0.3 0.225
Estimated GFR, ml/min/1.73 m2 94.4 ± 27.6 95.8 ± 23.1 93.3 ± 30.7 0.243
Hemoglobin, g/dL 13.4 ± 1.9 14.5 ± 2.0 12.6 ± 1.4 < 0.001
Serum albumin, g/dL 4.3 ± 0.5 4.4 ± 0.5 4.3 ± 0.5 < 0.001
Serum total cholesterol, mg/dL 189 ± 45 185 ± 44 192 ± 46 0.048
Serum triglyceride, mg/dL 170 ± 112 181 ± 128 160 ± 95 0.020
Serum HDL, mg/dL 51 ± 15 48 ± 15 53 ± 15 < 0.001
Urinary albumin excretion rate, μg/min 7.1 (4.2-18.7) 7.0 (4.3-19.6) 7.2 (4.1-17.6) 0.785
Hemoglobin A1c 9.0 ± 2.4 9.2 ± 2.5 8.9 ± 2.3 0.100
HOMA-IR 2.5 (1.6-3.9) 2.1 (1.4-3.3) 2.7 (1.8-4.6) < 0.001
Lipoprotein (a), (IU/L) 170 (50-389) 148 (34-351) 148 (59-402) 0.065
hs-CRP, mg/dL 0.2 (0.1-0.7) 0.2 (0.1-0.9) 0.2 (0.1-0.7) 0.815
Values are expressed as means ± SDs, medians (interquartile range) or n(%).
Table 2 Correlation coefficients of the relationships




BMI 0.182 < 0.001
Visceral fat area 0.230 < 0.001
Subcutaneous fat area 0.037 0.324
Systolic blood pressure 0.123 0.001
Diastolic blood pressure 0.090 0.017
Duration of diabetes 0.032 0.402
Serum creatinine 0.436 < 0.001
Estimated GFR -0.378 < 0.001
Hemoglobin 0.084 0.027
Serum albumin 0.089 0.019
Serum total cholesterol -0.018 0.641
Serum triglyceride 0.177 < 0.001
Serum HDL cholesterol -0.178 < 0.001
Urinary albumin excretion rate 0.110 < 0.001
Hemoglobin A1c -0.242 < 0.001
Log HOMA-IR 0.090 0.022
Log hs-CRP 0.088 0.026
Figure 1 Pearson’s correlation of the visceral fat area and the
subcutaneous fat area with the serum uric acid levels in
people with type 2 DM.
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higher in the visceral obesity group than that in the sub-
cutaneous obesity group, which suggested that visceral
fat accumulation may be associated with overproduction
of uric acid. Hikita et al reported that the serum uric
acid levels were related with both the visceral fat area
and the subcutaneous fat area in 508 Japanese man
industrial workers, which support the results of previous
study [14]. In our study, only the visceral fat area was
associated with the serum uric acid levels and subcuta-
neous fat area was not associated with the serum uric
acid levels, which is some different from the previous
studies. This discrepancy may be due to the differences
of the study designs or the populations of the studies. In
our study, only subjects with type 2 DM were recruited
while the previous study was a community-based study.
The amount of visceral fat area was greater and the
amount of subcutaneous fat area was less in people with
type 2 DM than that in the people with normal glucose
tolerance [16]. Furthermore, visceral fat area, but not
subcutaneous fat area, is associated with a decrease in
peripheral insulin sensitivity in type 2 DM [21], which
may decrease the urinary excretion of uric acid and this
may causes hyperuricemia especially in the subjects with
type 2 DM [22,23].
Some studies have suggested the mechanisms that link
visceral fat accumulation and an elevated serum uric
acid level. The visceral fat component has been regarded
as the more pathologic adipose tissue compartment as
compared with the subcutaneous fat component, and
the visceral fat component more strongly associated
with the cardiometabolic risk, as compared to that of
subcutaneous adiposity [8,9]. The visceral fat component
is metabolically active and it regulates numerous adipo-
cytokines such as leptin and adiponectin, which have
been associated with insulin resistance [24,25]. Insulin
resistance or hyperinsulinemia increases the reabsorp-
tion of sodium and uric acid on the renal tubules,
thereby decreasing the urinary excretion of uric acid
and this causes hyperuricemia [22,23]. In our study, the
insulin resistance (log HOMA-IR) was significantly cor-
related with the serum uric acid levels, which supports
the results of previous studies [22,23].
Another mechanism that visceral fat accumulation is
associated with the overproduction of uric acid has been
suggested by several investigators. Increased visceral fat
accumulation provides excessive free fatty acid in the
portal vein, which accelerates the overproduction of
very low-density lipoprotein and this causes hypertrigly-
ceridemia. This also accelerates the de novo purine
synthesis by NADPH produced in the pentose phos-
phate pathway which increases the uric acid production
[26,27]. In our study, the visceral fat area was more clo-
sely correlated with the serum triglyceride levels (r =
0.244, p < 0.001) than the subcutaneous fat area (r =
0.094, p = 0.012) (data not shown). The serum triglycer-
ide levels were positively associated with the serum uric
acid levels after adjustment for age, sex, systolic blood
pressure, diastolic blood pressure, BMI, serum creati-
nine, hemoglobin, serum albumin, serum HDL, serum
triglyceride, urinary albumin excretion and hemoglobin
A1c (b-coefficient = 0.109, p = 0.003) (data not shown),
and this all supports the relationships between uric acid
production and triglyceride synthesis.
Previous studies demonstrated that the reduced GFR
was correlated with hyperuricemia [28]. In our study,
eGFR was negatively related with serum uric acid levels
and the association was stronger between eGFR and
serum uric acid levels (r = -0.378, p < 0.001) than the
association between visceral fat area and serum uric acid
levels (r = 0.230, p < 0.001) (Table 2). To determine
whether the visceral fat area was associated with serum
uric acid levels independent of the reduced renal func-
tion, we analyzed the association between visceral fat
area and serum uric acid levels in patients with normal
renal function (eGFR > 6o ml/min/1.73 m2). The num-
ber of patients with eGFR > 6o ml/min/1.73 m2 was 629
(90%) in our study. In patients with eGFR > 6o ml/min/
1.73 m2, the association between visceral fat area and
serum uric acid levels was stronger (r = 0.290, p <
0.001) than the association between eGFR and serum
uric acid levels (r = - 0.269, p < 0.001) (data not
shown). Furthermore, in the multivariate logistic
Table 3 Multivariate linear regression analysis for the
association of the serum uric acid levels with the
regional abdominal adipose tissue distribution
b-coefficient P value
Visceral fat area, Cm 0.117 < 0.001
Subcutaneous fat area, Cm 0.061 0.255
BMI, kg/m2 0.184 < 0.001
Adjusted for age, sex, systolic blood pressure, diastolic blood pressure, serum
creatinine, hemoglobin, serum albumin, serum high-density lipoprotein, serum
triglyceride and hemoglobin A1c
Table 4 Multivariate logistic regression analyses to
determine the predictor of hyperuricemia
Clinical variables Odds ratio 95% CI P value
Age 1.0 0.97-1.02 0.638
Gender (male) 13.58 6.56-28.18 < 0.001
Systolic blood pressure 1.01 0.99-1.03 0.377
Diastolic blood pressure 0.99 0.96-1.03 0.632
Estimated GFR < 6o ml/min/1.73 m2 16.75 7.06-39.77 < 0.001
Serum triglyceride 1.00 1.00-1.00 0.153
Visceral fat area tertiles
I (< 93 Cm2) 1
II (93 - 143 Cm2) 1.50 0.76-2.97 0.245
III (> 143 Cm2) 2.33 1.21-4.50 0.012
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regression analyses, visceral fat area was independently
associated with serum uric acid levels (Table 4). These
findings suggest that the visceral fat area was associated
with serum uric acid levels independent of the reduced
renal function.
In our study, hyperuricemia is more prevalent in
males than in females, which was consistent with pre-
vious studies [19]. This finding may be due that estro-
gen promotes more efficient renal clearance of uric acid
[29]. It would be interesting to analyze the associations
between hyperuricemia and the regional abdominal adi-
pose tissue distribution separately in males and females.
However, in our study, the sample size of subjects with
hyperuricemia in females (n = 18) was relatively small
to generate the significant results by statistical analysis.
Therefore, we analyzed the association of visceral fat
area tertiles for hyperuricemia in both genders in logis-
tic regression model including gender as independent
variables (Table 4). The incidence of hyperuricemia was
statistically significant increases in the group with high
visceral fat area after adjustment of clinical variables
including gender. A larger study may elucidate the asso-
ciations separately in males and females.
Our study has several limitations. First, our study was
the cross-sectional study; therefore, it is difficult to infer
causality between visceral fat accumulation and the
serum uric acid levels. Second, this study was a single
center study; thus, it is uncertain whether our results
are generalizable to other ethnic groups with type 2
DM. Third, we did not examined urinary uric acid levels
in our study. Therefore, we could not analyze the asso-
ciation between uric acid metabolism or the type of
hyperuricemia and the regional distribution of abdom-
inal adipose tissue. Fourth, smoking habit or adipokines
such as leptin may influence the distribution of regional
abdominal adiposity and insulin resistance [30,31].
Unfortunately, the clinical information in our study did
not include the smoking history or adipokines. It would
be interesting to analyze the associations between smok-
ing habit or adipokines levels and abdominal adiposity
and serum uric acid levels.
Despite the above limitations, the present study is the
first to investigate the differential association between
the abdominal fat compartment and the serum uric acid
levels in people with type 2 DM and who have a differ-
ent regional abdominal adipose tissue distribution com-
pared to that of people with normal glucose tolerance.
Conclusions
The visceral fat area was positively associated with the
serum uric acid levels, but the subcutaneous fat area
was not in people with type 2 DM. Our data suggests
that the visceral adiposity may be more metabolically
active and it may be associated with an increased risk of
hyperuricemia, as compared to that of subcutaneous
adiposity in people with type 2 DM. Furthermore, per-
vious study reported that the changes of serum uric acid
were correlated with the changes of visceral fat thick-
ness but not with the changes of subcutaneous fat thick-
ness 1 year after bariatric restrictive surgery in morbidly
obese subjects [32]. Therefore, it may be postulated that
the efforts to decrease the visceral fat accumulation may
be helpful to prevent hyperuricemia and reduce the risk
of cardiovascular disease in people with type 2 DM
[32,33].
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